Intracerebroventricular injection of interleukin-1β induces hyperalgesia in rats

Takakazu Oka, Shuji Aou, Tetsuro Hori

Research output: Contribution to journalArticle

137 Citations (Scopus)

Abstract

To determine whether interleukin-1β (IL-1β) in the brain may modulate nociception, recombinant human IL-1β (rhIL-1β) (1pg/kg to 1 μg/kg) was microinjected into lateral cerebral ventricle of rats and the latency before initiating the licking of their hindpaws after being placed on a hot plate (50.0 ± 0.1°C) was measured. A significant reduction of the paw-lick latency was observed after injections of nonpyrogenic doses (10 pg/kg to 1 ng/kg) of rhIL-1β, showing a maximal response at a dose of 100 pg/kg which began to appear 5 min after injection, reached a peak within 30 min and then gradually subsided. An increase in the amount of rhIL-1β to > 1 ng/kg (up to 1 μg/kg had no effect on the nociceptive threshold. The rhIL-1β-induced hyperalgesia was completely abolished by pretreatment with an IL-1 receptor antagonist (IL-1ra) or Na salicylate. Similar pretreatment with α-melanocyte-stimulating hormone (α-MSH) also inhibited the rhIL-1β-induced hyperalgesia. However, pretreatment with α-helical corticotropin-releasing factor (CRF)9-41 failed to affect it. The results suggest that IL-1β in the brain produces hyperalgesia by its receptor-mediated and prostaglandin-dependent action which is sensitive to α-MSH. The hyperalgesic action of central IL-1 does not appear to depende on the CRF system.

Original languageEnglish
Pages (from-to)61-68
Number of pages8
JournalBrain Research
Volume624
Issue number1-2
DOIs
Publication statusPublished - Oct 8 1993

Fingerprint

Hyperalgesia
Interleukin-1
Injections
Melanocyte-Stimulating Hormones
Prostaglandin Receptors
Cerebral Ventricles
Nociception
Interleukin-1 Receptors
Salicylates
Lateral Ventricles
Corticotropin-Releasing Hormone
Brain

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Molecular Biology
  • Clinical Neurology
  • Developmental Biology

Cite this

Intracerebroventricular injection of interleukin-1β induces hyperalgesia in rats. / Oka, Takakazu; Aou, Shuji; Hori, Tetsuro.

In: Brain Research, Vol. 624, No. 1-2, 08.10.1993, p. 61-68.

Research output: Contribution to journalArticle

Oka, Takakazu ; Aou, Shuji ; Hori, Tetsuro. / Intracerebroventricular injection of interleukin-1β induces hyperalgesia in rats. In: Brain Research. 1993 ; Vol. 624, No. 1-2. pp. 61-68.
@article{926072baca844642b9ac649f24dca67c,
title = "Intracerebroventricular injection of interleukin-1β induces hyperalgesia in rats",
abstract = "To determine whether interleukin-1β (IL-1β) in the brain may modulate nociception, recombinant human IL-1β (rhIL-1β) (1pg/kg to 1 μg/kg) was microinjected into lateral cerebral ventricle of rats and the latency before initiating the licking of their hindpaws after being placed on a hot plate (50.0 ± 0.1°C) was measured. A significant reduction of the paw-lick latency was observed after injections of nonpyrogenic doses (10 pg/kg to 1 ng/kg) of rhIL-1β, showing a maximal response at a dose of 100 pg/kg which began to appear 5 min after injection, reached a peak within 30 min and then gradually subsided. An increase in the amount of rhIL-1β to > 1 ng/kg (up to 1 μg/kg had no effect on the nociceptive threshold. The rhIL-1β-induced hyperalgesia was completely abolished by pretreatment with an IL-1 receptor antagonist (IL-1ra) or Na salicylate. Similar pretreatment with α-melanocyte-stimulating hormone (α-MSH) also inhibited the rhIL-1β-induced hyperalgesia. However, pretreatment with α-helical corticotropin-releasing factor (CRF)9-41 failed to affect it. The results suggest that IL-1β in the brain produces hyperalgesia by its receptor-mediated and prostaglandin-dependent action which is sensitive to α-MSH. The hyperalgesic action of central IL-1 does not appear to depende on the CRF system.",
author = "Takakazu Oka and Shuji Aou and Tetsuro Hori",
year = "1993",
month = "10",
day = "8",
doi = "10.1016/0006-8993(93)90060-Z",
language = "English",
volume = "624",
pages = "61--68",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Intracerebroventricular injection of interleukin-1β induces hyperalgesia in rats

AU - Oka, Takakazu

AU - Aou, Shuji

AU - Hori, Tetsuro

PY - 1993/10/8

Y1 - 1993/10/8

N2 - To determine whether interleukin-1β (IL-1β) in the brain may modulate nociception, recombinant human IL-1β (rhIL-1β) (1pg/kg to 1 μg/kg) was microinjected into lateral cerebral ventricle of rats and the latency before initiating the licking of their hindpaws after being placed on a hot plate (50.0 ± 0.1°C) was measured. A significant reduction of the paw-lick latency was observed after injections of nonpyrogenic doses (10 pg/kg to 1 ng/kg) of rhIL-1β, showing a maximal response at a dose of 100 pg/kg which began to appear 5 min after injection, reached a peak within 30 min and then gradually subsided. An increase in the amount of rhIL-1β to > 1 ng/kg (up to 1 μg/kg had no effect on the nociceptive threshold. The rhIL-1β-induced hyperalgesia was completely abolished by pretreatment with an IL-1 receptor antagonist (IL-1ra) or Na salicylate. Similar pretreatment with α-melanocyte-stimulating hormone (α-MSH) also inhibited the rhIL-1β-induced hyperalgesia. However, pretreatment with α-helical corticotropin-releasing factor (CRF)9-41 failed to affect it. The results suggest that IL-1β in the brain produces hyperalgesia by its receptor-mediated and prostaglandin-dependent action which is sensitive to α-MSH. The hyperalgesic action of central IL-1 does not appear to depende on the CRF system.

AB - To determine whether interleukin-1β (IL-1β) in the brain may modulate nociception, recombinant human IL-1β (rhIL-1β) (1pg/kg to 1 μg/kg) was microinjected into lateral cerebral ventricle of rats and the latency before initiating the licking of their hindpaws after being placed on a hot plate (50.0 ± 0.1°C) was measured. A significant reduction of the paw-lick latency was observed after injections of nonpyrogenic doses (10 pg/kg to 1 ng/kg) of rhIL-1β, showing a maximal response at a dose of 100 pg/kg which began to appear 5 min after injection, reached a peak within 30 min and then gradually subsided. An increase in the amount of rhIL-1β to > 1 ng/kg (up to 1 μg/kg had no effect on the nociceptive threshold. The rhIL-1β-induced hyperalgesia was completely abolished by pretreatment with an IL-1 receptor antagonist (IL-1ra) or Na salicylate. Similar pretreatment with α-melanocyte-stimulating hormone (α-MSH) also inhibited the rhIL-1β-induced hyperalgesia. However, pretreatment with α-helical corticotropin-releasing factor (CRF)9-41 failed to affect it. The results suggest that IL-1β in the brain produces hyperalgesia by its receptor-mediated and prostaglandin-dependent action which is sensitive to α-MSH. The hyperalgesic action of central IL-1 does not appear to depende on the CRF system.

UR - http://www.scopus.com/inward/record.url?scp=0027304730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027304730&partnerID=8YFLogxK

U2 - 10.1016/0006-8993(93)90060-Z

DO - 10.1016/0006-8993(93)90060-Z

M3 - Article

VL - 624

SP - 61

EP - 68

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1-2

ER -